Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.01 (market cap $600.54M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 12.5× Direxion Daily FTSE China Bull 3x Shares's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| SYRE | YINN | |
|---|---|---|
Market Cap | $7.52B | $600.54M |
Volume | 1,441,031 | 729,546 |
Sector | Health | Leveraged / Inverse |
52-Week High | $108.92 | $52.69 |
52-Week Low | $22.18 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $6.52B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
YINN trades at $25.06, up 0.36% with bearish technical signals from moving averages. The stock shows neutral momentum oscillators with RSI at 44.85. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific financial metrics remain undisclosed in current data. The stock faces concentrated support/resistance around $25.
Outlook remains cautious with technical indicators suggesting bearish pressure. Investment opportunity depends on China's economic recovery and policy developments. Key risks include regulatory changes and market volatility. Analyst consensus and institutional positioning data are currently unavailable for assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
